Following its failure in pancreatic cancer (#msg-167645887), TYME became a shell company with significant cash (#msg-168370010); hence, this buyout is essentially a financing transaction for SYRS. The deal value (excluding a separate financing transaction by SYRS announced today) is about $70M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.